MDXH
MDxHealth S.A.
There isn't enough reported data to score MDXH yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
MDXH Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
MDXH's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MDXH PE Valuation
MDXH has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MDXH Forward outlook
There aren't enough analyst estimates for MDXH to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MDXH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.67 | +$0.49 |
| Q4 2024 | -$1.16 | +$0.50 |
| Q4 2023 | -$1.66 | +$1.14 |
MDXH and NVO do not have enough comparable growth data to identify a winner.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
MDXH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $107.9M | +20% |
| Q4 2024 | $90M | +28% |
| Q4 2023 | $70.2M | +89% |
| Q4 2022 | $37.1M | +67% |
| Q4 2021 | $22.2M | +159% |
| Q4 2020 | $8.6M | +841% |
| Q2 2020 | $9.9M | -9.1% |
| Q4 2019 | $912K | -92% |
MDXH has the edge over NVO in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -13% | +107 points |
| Q4 2024 | -27% | +137 points |
| Q4 2023 | -39% | +93 points |
| Q4 2022 | -102% | +2766 points |
| Q4 2021 | -121% | +6.8 points |
| Q4 2020 | -165% | -12 points |
| Q2 2020 | -131% | -45 points |
| Q4 2019 | -2868% | -2790 points |
MDXH's operating margin was −13% last quarter, up 107 points from the same quarter a year ago, near the top of its range since 2009.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
MDXH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$3.3M | +$16.4M |
| Q4 2024 | -$19.7M | +$4.5M |
| Q4 2023 | -$24.2M | +$12.7M |
| Q4 2022 | -$36.9M | -$13.5M |
| Q4 2021 | -$23.4M | -$14.1M |
| Q4 2020 | -$9.4M | -$863K |
| Q2 2020 | -$11.4M | +$2.4M |
| Q4 2019 | -$8.5M | -$1.7M |
MDXH has burned cash in almost every quarter: −$84M over the past year, against −$53M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
MDXH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +52% | +17.1M shares |
| 1 year | +454% | +40.9M shares |
| 3 years | +966% | +45.3M shares |
| 5 years | +2164% | +47.8M shares |
| Available history | +3691% | +48.6M shares |
MDXH has 50M diluted shares, up 454% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
| Q2 2018 | — |
| Q4 2017 | — |
| Q2 2017 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MDXH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MDXH Net Leverage
MDXH's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MDXH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.4 | Oversold |
| Stochastic | 0.7 | Oversold |
MDXH's weekly RSI is 24 (oversold) and its Stochastic is 1 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MDXH PE vs Healthcare Sector
MDXH has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MDXH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.32 | 56% below |
| 20 week MA | $0.48 | 71% below |
| 50 week MA | $1.68 | 92% below |
| 100 week MA | $2.14 | 93% below |
NVO has stronger trend alignment. MDXH is above 0 of 4 weekly averages versus NVO above 1 of 5.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
MDXH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $3.07 | $3.94 | +28% |
| 2024 | $3.94 | $2.31 | -41% |
| 2025 | $2.31 | $3.41 | +48% |
| 2026 YTD | $3.41 | $0.14 | -96% |
MDXH is down 96% so far in 2026, after finishing higher in two of the previous three years.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over MDXH on returns for 2026, with the stronger performance.